成人体外膜氧合循环辅助专家共识

2018-03-27 中国医师协会体外生命支持专业委员会 中华医学杂志.2018.98(12):886-894.

尽管ECMO技术已相对成熟,但对于ECMO辅助时机选择、适应证以及辅助期间患者管理等相关问题,不同ECMO中心存在一定差异,影响了ECMO辅助效果的判定。已有的ECMO循环辅助研究主要以病例报道和回顾性队列研究为主,尚缺乏高级别循证医学证据,其临床有效性和安全性有待进一步验证在我国,虽然越来越多的急性循环衰竭患者,如心源性休克(CS)或心跳骤停(CA)患者,接受了ECMO辅助,但相关共识缺乏。鉴于

中文标题:

成人体外膜氧合循环辅助专家共识

发布日期:

2018-03-27

简要介绍:

尽管ECMO技术已相对成熟,但对于ECMO辅助时机选择、适应证以及辅助期间患者管理等相关问题,不同ECMO中心存在一定差异,影响了ECMO辅助效果的判定。已有的ECMO循环辅助研究主要以病例报道和回顾性队列研究为主,尚缺乏高级别循证医学证据,其临床有效性和安全性有待进一步验证在我国,虽然越来越多的急性循环衰竭患者,如心源性休克(CS)或心跳骤停(CA)患者,接受了ECMO辅助,但相关共识缺乏。鉴于此,在国际ECMO循环辅助应用指南以及循证医学研究进展的基础下,结合我国应用现状,由中国医师协会体外生命支持专业委员会牵头制定此版成人循环衰竭ECMO辅助的专家共识。本共识涉及基础理论、ECMO建立、辅助期间管理和团队建设等内容,供国内ECMO从业人员参考。

 

拓展指南:循环相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=成人体外膜氧合循环辅助专家共识)] GetToolGuiderByIdResponse(projectId=1, id=eb5ed1c0015ea54a, title=成人体外膜氧合循环辅助专家共识, enTitle=, guiderFrom=中华医学杂志.2018.98(12):886-894., authorId=null, author=, summary=尽管ECMO技术已相对成熟,但对于ECMO辅助时机选择、适应证以及辅助期间患者管理等相关问题,不同ECMO中心存在一定差异,影响了ECMO辅助效果的判定。已有的ECMO循环辅助研究主要以病例报道和回顾性队列研究为主,尚缺乏高级别循证医学证据,其临床有效性和安全性有待进一步验证在我国,虽然越来越多的急性循环衰竭患者,如心源性休克(CS)或心跳骤停(CA)患者,接受了ECMO辅助,但相关共识缺乏。鉴于, cover=, journalId=null, articlesId=null, associationId=1622, associationName=中国医师协会体外生命支持专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Tue Mar 27 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>尽管ECMO技术已相对成熟,但对于ECMO辅助时机选择、适应证以及辅助期间患者管理等相关问题,不同ECMO中心存在一定差异,影响了ECMO辅助效果的判定。已有的ECMO循环辅助研究主要以病例报道和回顾性队列研究为主,尚缺乏高级别循证医学证据,其临床有效性和安全性有待进一步验证在我国,虽然越来越多的急性循环衰竭患者,如心源性休克(CS)或心跳骤停(CA)患者,接受了ECMO辅助,但相关共识缺乏。鉴于此,在国际ECMO循环辅助应用指南以及循证医学研究进展的基础下,结合我国应用现状,由中国医师协会体外生命支持专业委员会牵头制定此版成人循环衰竭ECMO辅助的专家共识。本共识涉及基础理论、ECMO建立、辅助期间管理和团队建设等内容,供国内ECMO从业人员参考。 </P> <P> </P>拓展指南:<STRONG>与<FONT color=red>循环</FONT>相关指南:</STRONG><BR> <UL> <LI><A title="2018 ESICM第二共识:重症患者舌下微循环的评估" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=a57731c00155a669">2018 ESICM第二共识:重症患者舌下微循环的评估</A> <LI><A title=缺血性卒中脑侧支循环评估与干预中国指南(2017) target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=0ad021c001a882a8">缺血性卒中脑侧支循环评估与干预中国指南(2017)</A> <LI><A title=静脉血栓栓塞症抗凝治疗微循环血栓防治专家共识 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=8243d1c001a8e7b4">静脉血栓栓塞症抗凝治疗微循环血栓防治专家共识</A> <LI><A title="2017 AHA科学声明:门诊和社区患者护理应用机械循环支持建议" target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=423411c001a4e433">2017 AHA科学声明:门诊和社区患者护理应用机械循环支持建议</A> <LI><A title=糖尿病微循环障碍临床用药专家共识 target=_blank href="http://www.medsci.cn/guideline/show_article.do?id=094761c001a44164">糖尿病微循环障碍临床用药专家共识</A> 更多信息请点击:<A target=_blank href="http://www.medsci.cn/guideline/list.do?q=%E5%BE%AA%E7%8E%AF">有关循环更多指南</A></LI></UL>, tagList=[TagDto(tagId=50233, tagName=体外膜氧合), TagDto(tagId=72523, tagName=循环辅助)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=14965, appHits=318, showAppHits=0, pcHits=13301, showPcHits=2251, likes=103, shares=17, comments=4, approvalStatus=1, publishedTime=Sun Apr 01 21:20:43 CST 2018, publishedTimeString=2018-03-27, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Apr 01 21:20:43 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 23:46:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=成人体外膜氧合循环辅助专家共识)])
成人体外膜氧合循环辅助专家共识
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1206932, encodeId=6feb1206932ea, content=学习中感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Tue Mar 29 15:53:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887101, encodeId=724388e101e5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/6239c92bd2854fc184f98af3b3c328e6/4144d0a94a5544889b3b0dc7a0287a0b.jpg, createdBy=24da2298559, createdName=Shinn梦, createdTime=Mon Sep 21 14:52:39 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301911, encodeId=6e6330191129, content=很实用的文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 02 05:31:49 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301822, encodeId=84fb3018225f, content=学习了.谢谢分享., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Apr 01 22:22:55 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2022-03-29 40386

    学习中感谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1206932, encodeId=6feb1206932ea, content=学习中感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Tue Mar 29 15:53:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887101, encodeId=724388e101e5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/6239c92bd2854fc184f98af3b3c328e6/4144d0a94a5544889b3b0dc7a0287a0b.jpg, createdBy=24da2298559, createdName=Shinn梦, createdTime=Mon Sep 21 14:52:39 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301911, encodeId=6e6330191129, content=很实用的文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 02 05:31:49 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301822, encodeId=84fb3018225f, content=学习了.谢谢分享., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Apr 01 22:22:55 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2020-09-21 Shinn梦

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1206932, encodeId=6feb1206932ea, content=学习中感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Tue Mar 29 15:53:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887101, encodeId=724388e101e5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/6239c92bd2854fc184f98af3b3c328e6/4144d0a94a5544889b3b0dc7a0287a0b.jpg, createdBy=24da2298559, createdName=Shinn梦, createdTime=Mon Sep 21 14:52:39 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301911, encodeId=6e6330191129, content=很实用的文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 02 05:31:49 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301822, encodeId=84fb3018225f, content=学习了.谢谢分享., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Apr 01 22:22:55 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2018-04-02 张新亮1853311252142e2fm

    很实用的文献.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1206932, encodeId=6feb1206932ea, content=学习中感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210201/f9ebd76673be43709bf11ecf3e05d29a/4ceebf8544374796ac74a7ce757d6c8f.jpg, createdBy=28e01512509, createdName=40386, createdTime=Tue Mar 29 15:53:52 CST 2022, time=2022-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=887101, encodeId=724388e101e5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201117/6239c92bd2854fc184f98af3b3c328e6/4144d0a94a5544889b3b0dc7a0287a0b.jpg, createdBy=24da2298559, createdName=Shinn梦, createdTime=Mon Sep 21 14:52:39 CST 2020, time=2020-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301911, encodeId=6e6330191129, content=很实用的文献.学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Apr 02 05:31:49 CST 2018, time=2018-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301822, encodeId=84fb3018225f, content=学习了.谢谢分享., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Apr 01 22:22:55 CST 2018, time=2018-04-01, status=1, ipAttribution=)]
    2018-04-01 惠映实验室

    学习了.谢谢分享.

    0